Hostname: page-component-84b7d79bbc-c654p Total loading time: 0 Render date: 2024-07-29T19:07:31.932Z Has data issue: false hasContentIssue false
  • English
  • Français

Duración del tratamiento del trastorno obsesivo compulsivo

Published online by Cambridge University Press:  12 May 2020

O. T. Dolberg ,
I. Iancu  and
J. Zohar
O. T. Dolberg
Affiliation:
División Psiquiátrica, Centro Médico , Sheba, Israel
I. Iancu
Affiliation:
División Psiquiátrica, Centro Médico , Sheba, Israel
J. Zohar
Affiliation:
División Psiquiátrica, Centro Médico , Sheba, Israel
Get access

Resumen

El primer avance en el tratamiento del trastorno obsesivo compulsivo (TOC) vino en 1967, cuando Fernández y López- Ibor informaron sobre la eficacia de la clomipramina (CMI) en el tratamiento de 16 pacientes con TOC (Fernández y López-Ibor, 1967). Sin embargo, hasta 1980 no se publicaron estudios controlados con CMI (Montgomery, 1980; Thoren et al, 1980), y únicamente en los últimos 5 años se han publicado estudios grandes bien controlados (Estudio de Colaboración de la Clomipramina, 1991). Varios estudios demostraron que, entre los tricíclicos (TCA), sólo la CMI es efectiva en el TOC, mientras que antidepresivos efectivos con un perfil noradrenérgico, como la desipramina (DMI), parecen ser totalmente inefectivos (Zohar e Insel, 1987; Goodman el al, 1990; Leonard et al, 1989). Esta respuesta selectiva a los TCA con un perfil serotoninérgico llevó a la formulación de la hipótesis serotoninérgica del TOC y al desarrollo y uso de otros agentes serotoninérgicos en el tratamiento de este trastorno. En la actualidad, se están investigando en todo el mundo varios fármacos que poseen este perfil, entre ellos, la CMI, la fluoxetina, la fluvoxamina, la sertralina, la paroxetina y el citalopram. En la actualidad, se conoce muy poco con respecto a la duración del tratamiento en el TOC, ya que el conocimiento referente al enfoque farmacológico para el TOC únicamente está comenzando a acumularse. En esta revisión intentaremos examinar los datos existentes con respecto a la duración del tratamiento en el TOC.

Keywords

trastorno obsesivo compulsivoclomipraminainhibidores de la recaptación de la serotonina
Type
Artículo Original
Information
European Psychiatry (Ed. Española) , Volume 4 , Issue 5 , July 1997 , pp. 293 - 297
Copyright
Copyright © European Psychiatric Association 1997

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Dolberg OT, Iancu I, Zohar J. Treatment duration of obsessive compulsive disorder. Eur Psychiatry 1996; 11: 403-406

References

Bibliografia

Chouinard, G. Sertraline in the treatment of obsessive compulsive disorder: Two double-blind, placebo-controlled studies. Int Clin Psychopharmacol 1992; 7 suppl: 37–41.CrossRefGoogle ScholarPubMed
Clomipramine collaborative study goup. Arch Gen Psychiatry 1991; 48: 730-8.CrossRefGoogle Scholar
Fernández, CELopez-Ibor, JJ. Monochlorimipramine in the treatment of psychiatric patients resistant to other therapies. Actas Luso-Espanolas Neurologia Psiquiatri y Ciencias Afines 1967; 26: 119-47.Google Scholar
Fontaine, RChouinard, G. Fluoxetine in the long-term maintenance treatment of obsessive-compulsive disorder. Psychiatr Ann 1989; 19: 88–91.CrossRefGoogle Scholar
Frenkel, ARosenthal, JNezu, AWinston, A. Efficacy of long-term fluoxetine treatment of obsessive-compulsive disorder. Mount Sinai J Med 1990; 57: 348-52.Google ScholarPubMed
Goodman, WKPrice, LH, Delgado PL et al. Specificity of serotoning reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Arch Gen Psvchiatry 1990; 47: 577-85.CrossRefGoogle Scholar
Greist, JJefferson, JW, Kobak KA et al. A 1-year double-blind placebo-controlles fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 1995; 10; 57–65.CrossRefGoogle Scholar
Leonard, HSwedo, S, Koby E et al. Treatment of obsessive- compulsive disorder with clomipramine and desmethylimipramine in children and adolescents: A double- blind crossover comparison. Arch Gen Psychiatry 1989; 46: 1088–92.CrossRefGoogle Scholar
Leonard, HLSwedo, SE, Lenane MC et al. A doubleblind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder. Arch Gen Psychiatry 1991; 48: 922-7.CrossRefGoogle Scholar
Leonard, HLSwedo, SE, Lenane MC et al. A 2-to 7-year follow-up study of 54 obsessive-compulsive children and adolescents. Arch Gen Psychiatry 1993; 50: 42939.CrossRefGoogle Scholar
Levine, RHoffman, JSKnepple, EDKenin, M. Longterm fluoxetine treatment of a large number of obsessive- compulsive patients. J Clin Psychiatry 1989; 9: 281-3.Google Scholar
Mallya, GKWhite, KWatemaux, CQuay, S. Short-and long-term treatment of obsessive-compulsive disorder with fluvoxamine. Ann Clin Psychiatry 1992; 4: 7780.CrossRefGoogle Scholar
Marks, IMStem, RS, Mawson D et al. Clomipramine and exposure for obsessive-compulsive rituals: I. Br J Psychiatry 1980; 136: 1–25.CrossRefGoogle Scholar
Mawson, DMarks, IMRamm, L. Clomipramine and exposure for chronic obsessive-compulsive rituals: III. Tow year follow-up and further findings. Br J Psychiatry 1982; 140: 11-8.CrossRefGoogle ScholarPubMed
Montgomery, SA. Clomipramine in obsessional neurosis: a placebo controlled trial. Pharmacologic Med 1980; 1: 89.Google Scholar
Orloff, LMBattle, MA, Baer L et al. Long-term followup of 85 patients with obsessive-compulsive disorder. Am J Psychiatry 1994; 151: 441-2.Google Scholar
O’Sullivan, GMarks, IM. Long-term outcome of phobic and OCD after exposure: a review. In: Noyes, R et al., eds. Handbook of Anxiety. Amsterdam: Elsevier Press, 1990.Google Scholar
Pato, MTZohar-Kadouch, RZohar, JMurphy, DL. Retum of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder. Am J Psychiatry 1988; 145: 1521–2.Google Scholar
Pato, MTHill, JLMurphy, DL. A clomipramine dosage reduction study in the course of long-term treatment of obsessive-compulsive disorder patients. Psychopharmacol Bull 1990; 26: 211-4.Google ScholarPubMed
Pollard, CAIbe, IO, Krojanker DN et al. Clomipramine treatment of trichotillomatnia. A follow-up report of four cases. J Clin Psychiatry 1991; 52: 128-30.Google Scholar
Ravizza, LBarzega, GBellino, S et al. Predictors of response and long-term treatment of obsessive-compulsive disorder. In: Darcourt, GMendlewicz, JRacagni, GBrunello, N, eds. Current Therapeutic Approaches to Panic and Other Anxiety Disorder. Basel: Karger: International Academy of Biomedical Drug Research, 1994; 164-70.Google Scholar
Steiner, MBushnell, WDGergel, IWheadon, DE. Long-term treatment and prevention of relapse of obsessive compulsive disorder with paroxetine. American psychiatric Association Annual Meeting, May 1995.Google Scholar
Thoren, PAsberg, M, Gronholm B et al. Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial. Arch Gen Psychiatry 1980; 37: 1281–5.CrossRefGoogle Scholar
Zohar, JInsel, T. Obsessive-compulsive disorder: Psychobiological approaches to diagnosis, treatment, and pathophysiology. Biol Psychiatry 1987; 22: 667-87.CrossRefGoogle ScholarPubMed